Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Refractory/Relapse Neuroblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Rituximab 57Cyclophosphamide 56fludarabine 37fludarabine phosphate 31Filgrastim 27Etoposide 22Bortezomib 20Melphalan 19Gemcitabine 19Cytarabine 17Bendamustine Hydrochloride 17Peripheral Blood Stem Cell Transplantation 16Vincristine 15pembrolizumab 14aldesleukin 13Prednisone 13Doxorubicin 12Dexamethasone 12Busulfan 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Sirolimus 11sargramostim 10obinutuzumab 10Lenalidomide 10romidepsin 9Radiotherapy 9Rifampin 8Paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma × Biological Products × Clear all
NCT01430390 2025-06-11

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡